Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report

Abstract

Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene is considerably more frequent in squamous cell lung cancer (SqCLC) than in other subtypes of lung cancer and may be a promising target for this histology. Here, we present the course of diagnosis and treatment of a patient with advanced SqCLC, harboring not only CDKN2A mutation but also PIK3CA amplification, Tumor Mutational Burden-High (>10 mutations/megabase), and a Tumor Proportion Score of 80%. After disease progression on multiple lines of chemotherapy and immunotherapy, he responded favorably to treatment with the CDK4/6i Abemaciclib and later achieved a durable partial response to immunotherapy rechallenge with a combination of anti-PD-1 and anti-CTLA-4, nivolumab, and ipilimumab.

Crosstalk among disulfidptosis-related lncRNAs in lung adenocarcinoma reveals a correlation with immune profile and clinical prognosis

“…TME is previously suggested to be associated with LUAD distant metastases, drug sensitivity, and immunotherapeutic response [ [24] , [25] , [26] ]. Stromal and immune cell levels within TME can be represented by stromal score and immune score, respectively.…”

Treatment with palbociclib and tislelizumab for CDKN2A-mutated and PD-L1-positive advanced intrahepatic cholangiocarcinoma: a case report and literature review

“…The patient responded well to CDK4/6 inhibitor abemaciclib therapy after experiencing disease progression with multiple chemotherapies and immunotherapy. A subsequent rechallenge with combined immunotherapy using Opdivo and ipilimumab resulted in a durable partial response ( 21 ).…”

State-of-the-Art Molecular Oncology in Brazil

“…Cancer therapy now includes conventional chemotherapy, photodynamic therapy, inhibitors of angiogenesis, targeted therapy, immunotherapy, CAR-T cell therapy, oncolytic viruses, and antitumor vaccines [3,4]. Additionally, combined therapies, the development of second-and thirdgeneration drugs, nanotechnological approaches, and drug repurposing have arisen as possible strategies to improve drug responsiveness and overcome drug resistance [5][6][7][8][9]. At last, the possibility of genome edition/correction by the CRISPR-Cas9 methodology represents a promising tool to be employed in treating cancer in the near future [10].…”